VivoSeq
Oncology

Recurrent Lung Non-Small Cell Carcinoma

8

Pipeline Programs↗

2

Active Trials↗

5

Companies Involved↗

Recurrent Lung Non-Small Cell Carcinoma is an early-stage landscape with 8 programs across 5 companies. The most active players are Avyxa, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc., AstraZeneca. 6 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

0/100

Mech. Concentration

25/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Avyxa

2 programs

Phase 3M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 3AstraZeneca logo

AstraZeneca

1 program

Phase 3Teva logo

Teva

1 program

Phase 3G

Gynecologic Oncology Group

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

83%

Small molecule

5 of 6 classified programs — the dominant modality here.

17%ALL OTHERSMonoclonal antibody117%

Small molecule leads; the ring shows all 6 classified programs, each share of the total. Modality classified for 75% of 8 pipeline programs.

Analysis

Trial Status

2

clinical trials

Active, not recruiting2 · 100%

Clinical Trials

Trial Activity

Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Active, not recruiting·National Cancer Institute (NCI)·Phase 3·NCT04092283·660 enrolled
A Randomized Phase II Trial of Erlotinib, Cabozantinib, or Erlotinib Plus Cabozantinib as 2nd or 3rd Line Therapy in Patients With EGFR Wild-Type NSCLC
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT01708954·125 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)